Faculty Chairs & Presenters

 

Program Overview

This program will focus on describing the mechanisms of action of current and emerging therapies in multiple myeloma and review their efficacy and safety profiles across different treatment settings. The program will also integrate patient-specific factors, prognostic indicators, and current evidence to design and implement personalized treatment plans across multiple lines of therapy. Lastly, comprehensive management strategies for patients receiving immunotherapies will be reviewed. This will include referrals to specialized treatment centers, patient and caregiver education, expected outcomes, potential complications, and proactive monitoring.

Target Audience

This activity is designed to meet the educational needs of academic and community hematologists/oncologists, oncology nurses, oncology nurse practitioners/physician assistants, and oncology pharmacists to ensure the appropriate use of current and emerging therapies in relapsed/refractory multiple myeloma.

Learning Objectives

Upon the completion of this program, attendees should be able to:

• Describe the mechanisms of action of current and emerging therapies in multiple myeloma, critically assessing their efficacy and safety profiles across different treatment settings.
• Integrate patient-specific factors, prognostic indicators, and current evidence to design and implement personalized treatment plans for patients with multiple myeloma, integrating innovative antibody and immunotherapy platforms across all lines of therapy.
• Develop comprehensive management strategies for patients with multiple myeloma receiving immunotherapies, addressing criteria and timing for referral to specialized treatment centers, patient and caregiver education on expected outcomes and potential complications, and proactive monitoring and management of unique toxicities related to treatment.

Joint Accreditation Statement

Physician Credit Designation Statement

Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hour.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Disclosure of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Method of Participation

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.